They know exactly how much it costs and how much the opposition charge per test in every market they are entering, They know the market size and have spent many months signing up partners and you can bet they know exactly how long they have the rights to licences in they're contracts. They have the CE mark for Europe which all EU governments recognise as they're gold standard. All of your questions are known to RHY, and they are very advanced into the commercialisation phase, however, there does not appear to be any actual sales or trials. If there is a stumbling block in Europe, then I would like to know what it is and if its surmountable or not. It may be as simple as exisiting tests are contracted for years to come or Doctors are not prepared to take the risk of prescribing a new tech. Perhaps they're too busy with covid and colon checks are on the back burner for now, due to staffing issues and Government restrictions, etc. I thought maybe some one else had some info they had picked up or researched that could shed some light on the lack of sales.
RHY Price at posting:
$1.36 Sentiment: Hold Disclosure: Held
